Overview
McDermott Will & Emery has advised Corteria Pharmaceuticals, a French biotechnology company specialising in the development of therapies for certain forms of heart failure, on the completion of a EUR 65 million Series A financing round led by two new investors, French Jeito Capital and US Orbimed, with the participation of all of the previous investors (Kurma Partners, Fountain Healthcare Partners, V-Bio Ventures, Invivo Capital, Omnes Capital).
This transaction should enable Corteria to advance its cardiovascular pipeline towards the clinical stage. Corteria’s innovative approach focuses on the selection of therapeutic targets involved in acute and worsening forms of human heart failure, as well as a stratification strategy designed to identify the specific sub-groups most likely to benefit from treatment. These forms of heart failure are widespread, life-threatening and not directly managed by current standards of care.
The McDermott team that advised Corteria Pharmaceuticals included :
- Anthony Paronneau, partner, Lucie Martin and Natacha Vasak, associates on Corporate and Life Sciences aspects
- Côme de Saint-Vincent, Counsel, on Tax aspects
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
